

SARS-CoV-2

An evolving pandemic


Sarah (Sally) Otto
Department of Zoology
University of British Columbia



BC COVID-19 Modelling Group

The BC COVID-19 Modelling Group works on rapid response modelling of the COVID-19 pandemic, with a special focus on British Columbia and Canada.

The interdisciplinary group, working independently from Government, includes experts in epidemiology, mathematics, and data analysis from UBC, SFU, UVic, and the private sector, with support from the Pacific Institute for the Mathematical Sciences.



<https://bccovid-19group.ca>

Weekly meetings

- Review relevant articles
- Expert presentations
- Present new models for feedback
- Request help with projects
- Provide advice

Slack channel

- News updates
- Communications channel
- Community building

Public reports

- <https://bccovid-19group.ca>

*Independent and freely offered advice,
using a diversity of modelling approaches.*


Coronavirus Variants
Rapid Response
Network



Réseau de réponse
rapide aux variants
du coronavirus

A year later, a broader network of Canadian scientists launched CoVaRR-Net (Coronavirus Variants Rapid Response Network, <https://covarrnet.ca>) with the goal of tracking and assessing the impact of variants.

Network brings together immunologists, bioinformaticians, molecular & cellular biologists, public health experts, and evolutionary biologists.



Coronavirus Variants
Rapid Response
Network




Réseau de réponse
rapide aux variants
du coronavirus

A year later, a broader network of Canadian scientists launched CoVaRR-Net (Coronavirus Variants Rapid Response Network, <https://covarrnet.ca>) with the goal of tracking and assessing the impact of variants.

Network brings together immunologists, bioinformaticians, molecular & cellular biologists, public health experts, and evolutionary biologists.

Evolution...of how we conduct science to aid action





Genomic epidemiology of novel coronavirus - Global subsampling



Maintained by the Nextstrain team. Enabled by data from **GISAID**

Showing 3960 of 3960 genomes sampled between Dec 2019 and Mar 2021.


Phylogeny

Clade ^

19A
19B
20A
20B
20C
20D

20E (EU1)
20F
20G
20H/501Y.V2
20I/501Y.V1
20J/501Y.V3

ZOOM TO SELECTED



<https://nextstrain.org/ncov?l=radial>

Sequences coalesce
in Nov/Dec 2019


First year did not show
strong signs of
selective sweeps
(star-shaped tree)

~11,000,000 genomes!!

Rate of substitution:
= 0.0008/bp/year
(about once per
genome every two
weeks)

Variants of Concern

Public Health England (Dec. 21, 2020) reported a Variant of Concern (VOC) B.1.1.7 that had increased in frequency across multiple weeks and across multiple health authorities.



Data from Public Health England
(visual from Theo Sanderson)



Genomic epidemiology of novel coronavirus - Global subsampling

Built with [nextstrain/ncov](#). Maintained by the [Nextstrain team](#). Enabled by data from [GISAID](#).

Showing 3044 of 3044 genomes sampled between Dec 2019 and Feb 2022.

Phylogeny


Clade ^



Second year
characterized by
waves of variants of
concern (VoCs)

<https://nextstrain.org/ncov?l=radial>

Modelling selection on SARS-CoV-2



 Current Biology

[Day et al. \(2020\)](#)

[Otto et al. \(2022\)](#)

SEAPIR Model

$$\frac{dS}{dt} = -S \sum_{*} (\beta_P^* P^* + \beta_I^* I^* + \beta_A^* A^*)$$

Non-linear set of equations is approximately linear when susceptible class is not changing rapidly ($S \sim \text{constant}$)


$$\frac{dE^*}{dt} = S(\beta_P^* P^* + \beta_I^* I^* + \beta_A^* A^*) - \kappa_E^* E^*$$

$$\frac{dA^*}{dt} = f^* \kappa_E^* E^* - \kappa_A^* A^*$$

$$\frac{dP^*}{dt} = (1 - f^*) \kappa_E^* E^* - \kappa_P^* P^*$$

$$\frac{dI^*}{dt} = \kappa_P^* P^* - (\alpha^* + \kappa_I^*) I^*$$

$$\frac{dR}{dt} = \sum_{*} (\kappa_I^* I^* + \kappa_A^* A^*)$$



SEAPIR Model

$$\frac{dS}{dt} = -S \sum_* (\beta_P^* P^* + \beta_I^* I^* + \beta_A^* A^*)$$

Non-linear set of equations is approximately linear when susceptible class is not changing rapidly ($S \sim \text{constant}$)

⚡ Add mutations (*) and track spread of new lineage


$$\frac{dE^*}{dt} = S(\beta_P^* P^* + \beta_I^* I^* + \beta_A^* A^*) - \kappa_E^* E^*$$

$$\frac{dA^*}{dt} = f^* \kappa_E^* E^* - \kappa_A^* A^*$$

$$\frac{dP^*}{dt} = (1 - f^*) \kappa_E^* E^* - \kappa_P^* P^*$$

$$\frac{dI^*}{dt} = \kappa_P^* P^* - (\alpha^* + \kappa_I^*) I^*$$

$$\frac{dR}{dt} = \sum_* (\kappa_I^* I^* + \kappa_A^* A^*)$$



SEAPIR Model


$$\frac{dS}{dt} = -S \sum_* (\beta_P^* P^* + \beta_I^* I^* + \beta_A^* A^*)$$

Non-linear set of equations is approximately linear when susceptible class is not changing rapidly ($S \sim \text{constant}$)

⚡ Add mutations (*) and track spread of new lineage

Calculate selection on life-history traits by effect of mutations on the spread of the disease (λ , leading eigenvalue):

$$\frac{d\lambda}{dz} = \vec{v}^T \frac{d\mathbf{M}}{dz} \vec{u}$$



$$\frac{dE^*}{dt} = S(\beta_P^* P^* + \beta_I^* I^* + \beta_A^* A^*) - \kappa_E^* E^*$$

$$\frac{dA^*}{dt} = f^* \kappa_E^* E^* - \kappa_A^* A^*$$

$$\frac{dP^*}{dt} = (1 - f^*) \kappa_E^* E^* - \kappa_P^* P^*$$


$$\frac{dI^*}{dt} = \kappa_P^* P^* - (\alpha^* + \kappa_I^*) I^*$$

$$\frac{dR}{dt} = \sum_* (\kappa_I^* I^* + \kappa_A^* A^*)$$

SEAPIR Model

What selection pressures are acting on SARS-CoV-2?

$$\begin{aligned} \frac{d\lambda}{dz} = & S v_E (\Delta\beta_P u_P + \Delta\beta_I u_I + \Delta\beta_A u_A) - (\Delta\alpha + \Delta\kappa_I) u_I v_I - \Delta\kappa_A u_A v_A - \Delta f \kappa_E u_E \{v_P - v_A\} \\ & + \Delta\kappa_E u_E \{(v_P(1-f) + f v_A) - v_E\} - \Delta\kappa_P u_P \{v_P - v_I\} \end{aligned}$$



SEAPIR Model


What selection pressures are acting on SARS-CoV-2?

$$\frac{d\lambda}{dz} = S v_E (\Delta\beta_P u_P + \Delta\beta_I u_I + \Delta\beta_A u_A) - (\Delta\alpha + \Delta\kappa_I) u_I v_I - \Delta\kappa_A u_A v_A - \Delta f \kappa_E u_E \{v_P - v_A\} + \Delta\kappa_E u_E \{(v_P(1-f) + f v_A) - v_E\} - \Delta\kappa_P u_P \{v_P - v_I\}$$

Mutant effects

Right eigenvector
(strictly positive)

Differences in left eigenvectors
Compares “reproductive values”




What selection pressures act on SARS-CoV-2 in a largely susceptible population?

Higher transmission

- Intrinsic transmissibility
- Immune evasion

Negligible direct selection on severity and mortality



Current Biology

Day et al. (2020)


Prolonged infectivity:

- Earlier infectivity favoured if cases rising
- Later infectivity favoured if cases declining

What selection pressures act on SARS-CoV-2 in a largely susceptible population?

Higher transmission

- Intrinsic transmissibility
- Immune evasion



Negligible direct selection on severity and mortality

Current Biology

Day et al. (2020)


Prolonged infectivity:

- Earlier infectivity favoured if cases rising
- Later infectivity favoured if cases declining

What selection pressures act on SARS-CoV-2 in a largely susceptible population?

“Virulence evolution will be driven largely by the indirect effects of pleiotropy...”


- Mutations might “couple a higher transmission rate with higher mortality (**positive pleiotropy**)...if mutations increase viral replication rates.”
- Alternatively, mutations might alter “tissue tropism such that the disease tends to preferentially infect cells of the upper respiratory tract, rather than the lower respiratory tract. Such infections could lead to a higher transmission rate but be less virulent (negative pleiotropy)”



What selection pressures act on SARS-CoV-2 in a largely susceptible population?

“Virulence evolution will be driven largely by the indirect effects of pleiotropy...”

- Mutations might “couple a higher transmission rate with higher mortality (**positive pleiotropy**)...if mutations increase viral replication rates.”
- Alternatively, mutations might alter “tissue tropism such that the disease tends to preferentially infect cells of the upper respiratory tract, rather than the lower respiratory tract. Such infections could lead to a higher transmission rate but be less virulent (negative pleiotropy)”



 Current Biology

Day et al. (2020)

Based on:

Lin et al. (2022) for Alpha, Beta, Gamma, Delta vs wildtype

Nyberg et al. (2022) for Omicron vs Delta (rescaled using above to wildtype)


Evolution in action

We can estimate selection using classical population genetics models for the change in frequency (p) of a variant due to selection (s):

$$\frac{dp}{dt} = s p (1 - p)$$

which can be solved:

$$p_t = \frac{e^{st} p_0}{1 - p_0 + e^{st} p_0}$$



Evolution in action

We can estimate selection using classical population genetics models for the change in frequency (p) of a variant due to selection (s):

$$\frac{dp}{dt} = s p (1 - p)$$


which can be solved:

$$p_t = \frac{e^{st} p_0}{1 - p_0 + e^{st} p_0}$$

with n_t sequences at time t and an observed number of each type (j, k), the likelihood of observing the data is binomial:

$$\text{likelihood}(\text{data}_t) = \binom{n_t}{j} p_t^j (1 - p_t)^k$$

$$\ln L(\text{all data}) \propto \sum_t j \ln(p_t) + k \ln(1 - p_t)$$



Evolution in action

We can estimate selection using classical population genetics models for the change in frequency (p) of a variant due to selection (s):

$$\frac{dp}{dt} = s p (1 - p)$$


which can be solved:

$$p_t = \frac{e^{st} p_0}{1 - p_0 + e^{st} p_0}$$

with n_t sequences at time t and an observed number of each type (j, k), the likelihood of observing the data is binomial:

$$\text{likelihood}(\text{data}_t) = \binom{n_t}{j} p_t^j (1 - p_t)^k$$

$$\ln L(\text{all data}) \propto \sum_t j \ln(p_t) + k \ln(1 - p_t)$$



Estimate selection by
maximizing the likelihood

Plus: get CI & allow for multiple variants

Evolution in action

We can estimate selection using classical population genetics models for the change in frequency (p) of a variant due to selection (s):

$$\frac{dp}{dt} = s p (1 - p)$$



which can be solved:

$$p_t = \frac{e^{st} p_0}{1 - p_0 + e^{st} p_0}$$

Or rearrange:

$$\text{Step 1: } \frac{p_t}{1 - p_t} = \frac{e^{st} p_0}{1 - p_0}$$

$$\text{Step 2: } \ln\left(\frac{p_t}{1 - p_t}\right) = s t + \ln\left(\frac{p_0}{1 - p_0}\right)$$




Predicts a linear relationship
with constant slope s if
selection is constant

SEAPIR Model

What selection pressures are acting on SARS-CoV-2?

$$\frac{d\lambda}{dz} = S v_E (\Delta\beta_P u_P + \Delta\beta_I u_I + \Delta\beta_A u_A) - (\Delta\alpha + \Delta\kappa_I) u_I v_I - \Delta\kappa_A u_A v_A - \Delta f \kappa_E u_E \{v_P - v_A\} \\ + \Delta\kappa_E u_E \{(\nu_P(1-f) + f v_A) - v_E\} - \Delta\kappa_P u_P \{v_P - v_I\}$$

Selection should weaken for a variant that increases transmission if susceptibles are protected and/or transmission is limited.





SEAPIR Model

What selection pressures are acting on SARS-CoV-2?

$$\frac{d\lambda}{dz} = S v_E (\Delta\beta_P u_P + \Delta\beta_I u_I + \Delta\beta_A u_A) - (\Delta\alpha + \Delta\kappa_I) u_I v_I - \Delta\kappa_A u_A v_A - \Delta f \kappa_E u_E \{v_P - v_A\} \\ + \Delta\kappa_E u_E \{v_P(1-f) + f v_A\} - \Delta\kappa_P u_P \{v_P - v_I\}$$

Selection should weaken for a variant that increases transmission if susceptibles are protected and/or transmission is limited.




SEAPIR Model




What selection pressures are acting on SARS-CoV-2?

$$\frac{d\lambda}{dz} = S v_E (\Delta\beta_P u_P + \Delta\beta_I u_I + \Delta\beta_A u_A) - (\Delta\alpha + \Delta\kappa_I) u_I v_I - \Delta\kappa_A u_A v_A - \Delta\kappa_P u_P \{v_P - v_I\} - \Delta\kappa_E u_E \{(\nu_P(1-f) + f\nu_A) - \nu_E\} - \Delta\kappa_P u_P \{v_P - v_I\}$$

Selection should weaken for a variant that increases transmission if susceptibles are protected and/or transmission is limited.




Collective concern



2022


Evolution in action

Omicron's BA.2 vs BA.1




2022


Evolution in action



Evolution in action




Evolution in action



Omicron: First major VOC to evade immunity

Three times more spike mutations than all other VOC had when they arose.

Many mutations are known or predicted to reduce efficacy of neutralizing antibodies and increase ACE2 binding.




Receptor Binding Domain

with residue mutated relative to the wild-type

[Kumar et al. \(2022\) J Med Vir](#)

The key mutations that shape Omicron




- ① The combination of mutations at K417N, S477N, Q498R and N501Y is thought to be an antibody-evasion strategy
- ② Deletions at positions 69 & 70 mean the variant can be detected using some PCR tests without the need for full genomic sequencing
- ③ Four new mutations: S371L, S373P and S375F are thought to create additional obstacles for certain antibodies
- ④ Three mutations: S477N, S477L and P681H may be associated with increased transmissibility

Sources: Ulrich Elling; Björn Meyer; Kevin McCarthy; covariants.org
© FT

Financial Times

Omicron

First detected in mid-November 2021¹,
Omicron shows a substantially older
evolutionary history, diverging from other
VOC near the beginning of the pandemic.



¹ [Viana et al. \(2022\)](#)

² [Tegally et al. \(2022\)](#)

Omicron Sub-Lineages

The mutation rates per unit time (slopes) are similar, but Omicron appears to have had a history of elevated mutation (a pulse raising the intercept).

Unusual evolutionary features of Omicron:

- more than expected number of mutations
- disproportionate number of changes in spike
- a long period of evolutionary divergence “out of sight” of global surveillance
- evidence that recombination was involved^{1,2} in the generation of at least one of BA.1-BA.5


¹ [Viana et al. \(2022\)](#)

² [Tegally et al. \(2022\)](#)

Coronavirus Variants
Rapid Response
Network




Réseau de réponse
rapide aux variants
du coronavirus



[Source: Art Poon]

Unusual evolutionary features of VOC




Black box: Passage through immunocompromised individual(s) with persistent infections¹ may account for these unusual features:

- High and prolonged viral replication (more mutations)
- Relaxed and/or altered immune environment, allowing mutations to accumulate in antigenic regions
- Hidden from surveillance efforts
- Higher potential for recombination²

¹ e.g., 335 days [in a lymphoma patient](#); >9 months in an [HIV patient](#)

² Recombination detected in a lymphoma patient infected for 14 months, initially infected with B.1.160 then with Alpha ([Burel et al.](#))

Unusual evolutionary features of VOC





[Harari et al. \(2022\)](#)

Unusual evolutionary features of VOC


Brief Report

SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape


Sandile Cele,^{1,2} Farina Karim,^{1,2} Gila Lustig,³ James Emmanuel San,⁴ Tandile Hermanus,^{5,6} Houriyah Tegally,^{4,7} Jumari Snyman,^{1,8} Thandeka Moyo-Gwete,^{5,6} Eduan Wilkinson,^{4,7} Mallory Bernstein,¹ Khadija Khan,^{1,2} Shi-Hsia Hwa,^{1,9} Sasha W. Tilles,¹⁰ Lavanya Singh,⁴ Jennifer Giandhari,⁴ Ntombifuthi Mthabela,¹ Matilda Mazibuko,¹ Yashica Ganga,¹ Bernadett I. Gosnell,¹¹ Salim S. Abdool Karim,^{3,12} Willem Hanekom,^{1,9} Wesley C. Van Voorhis,¹⁰ Thumbi Ndung'u,^{1,8} COMMIT-KZN Team,¹⁶ Richard J. Lessells,^{2,3,4} Penny L. Moore,^{3,5,6,13} Mahomed-Yunus S. Moosa,¹¹ Tulio de Oliveira,^{2,3,4,7,14} and Alex Sigal^{1,2,15,*}



Example of an immunocompromised patient with persistent (190 day) COVID infection, which evolved substantial escape from neutralization.



Evolution: Emergence of new variants



Most mutations will arise in prevailing lineages:

- Increases in transmissibility & immune escape (e.g., BA.4 & BA.5)

Major shifts may well arise outside of these lineages (less likely to elicit an immune response)

- Immunosuppressed individuals
- Human -> animal -> human zoonoses


New variants may be more (e.g., Alpha and Delta) or less (e.g., Omicron) severe.

Globally: Since May 1, 2022, Delta (37), Alpha (2), and a variety of other non-VOC lineages remain in circulation (0.2%).



Sub-variants BA.4 & BA.5

→ Very similar to BA.2, but called BA.4 and BA.5 because they lack some of the mutations characteristic of BA.2 (like S:Q493, NSP4 L438 and Orf6 D61). Diverged earlier?



S:L452R - increased ACE2 binding and infectivity; reduced antibody recognition
S:F486R - a key site for evasion of antibodies

[Tegally et al. \(2022\)](#)

Omicron Sub-Lineages


Early data from South Africa suggests an 8% per day selective advantage for BA.4 and 12% for BA.5 ([Tegally et al. 2022](#)), relative to BA.2.

Spread may result from a combination of **higher inherent transmissibility** and **immune evasion** ([Khan et al. 2022](#); [Hachmann et al.](#)).

Together, BA.4 & BA.5 are estimated to comprise >70% of global sequences by today

Global proportion

Estimated proportion through time



covSPECTRUM

Enabled by data from GISAID

$s = 9\%$ per day


83% per week

Current adv. ⓘ

79-86%

Confidence int. ⓘ

Estimated proportion through time



$s = 12\%$ per day

122% per week

Current adv. ⓘ

117-126%

Confidence int. ⓘ


Omicron sub-lineages in Canada

GISAID data shared by Public Health labs across Canada allow us to track the spread of Omicron sublineages over time.

→ BA.4 is spreading rapidly at a rate of $s=9.5\%$ per day relative to BA.2#

→ BA.5 is spreading slightly faster with $s=14\%$ per day relative to BA.2#

These lineages should now (or soon) dominate the COVID-19 picture in Canada.




Source (S. Otto) Canadian metadata was downloaded from GISAID for the Omicron GRA clades (Alberta sequences were removed as AB first identifies variants and preferentially sequences some subtypes). A model of selection was fit to the numbers of each type using maximum likelihood based on a trinomial distribution given the expected frequencies on each day. Hessian matrix used to obtain confidence intervals.

What does this imply for case numbers?

We'll use case numbers observed in individuals aged 70+ to assess trends, as they have been more consistently tested.


Cases among the 70+ age group are **significantly decreasing***.




Source (S. Otto) New cases per day in 10-year age groups were downloaded from the [BCCDC COVID-19 data portal](#). Cubic spline fits to log-case data were obtained (curves) for those 70+ (green) or <70 (blue). *Linear regression through log case counts among 70+ from last 14 days of data.

What does this imply for case numbers?

Fitting models of selection allows us to estimate frequency changes among variants.







Multiplying by the # of cases in those over 70 allows us to **estimate** growth in numbers of each Omicron sublineage.



→ While numbers of BA.1 and BA.2 are declining, **estimated numbers of BA.4 & BA.5 (grouped together) are rising ($r = +3.1\%$) in British Columbia.**

Source (S. Otto) Canadian metadata was downloaded from GISAID for the Omicron GRA clades. A model of selection was fit to the numbers of each type using maximum likelihood based on a trinomial distribution given the expected frequencies on each day. Hessian matrix used to obtain confidence intervals.

Daily growth rates




The Third Omicron Wave

The above projections indicate that **case numbers should start rising around July 1**, driven by a BA.4 & BA.5 wave.

This third Omicron wave should **peak about 4-8 weeks** afterwards.

Fairly high confidence




The Third Omicron Wave

The above projections indicate that **case numbers should start rising around July 1**, driven by a BA.4 & BA.5 wave.

This third Omicron wave should **peak about 4-8 weeks** afterwards.

Fairly high confidence



The **height & impact of this peak is challenging to predict**, depending on the interplay of many factors:


1. **Antibody levels**
2. **Efficacy of neutralizing antibodies**
3. **Virulence of BA.4 & BA.5**
4. **Public health measures**

No confidence

Factors determining the height of the BA.4/BA.5 wave

1. Antibody levels

The COVID-19 Immunity Task Force & Canadian Blood Services data suggests high standing levels of spike antibodies in all age groups (blood donations through mid-May 2022).




Good news


Factors determining the height of the BA.4/BA.5 wave

2. Efficacy of neutralizing antibodies: The ability of these antibodies to neutralize SARS-CoV-2 and prevent infection is substantially compromised for BA.4 & BA.5.

B Vaccinated Participants before and after Booster Dose



C Infected Participants with BA.1 or BA.2 Subvariant



[Hachmann et al, \(2022\) NEJM](#)


Factors determining the height of the BA.4/BA.5 wave

3. **Virulence:** Currently have no clear indication of the relative virulence of BA.1-BA.5

In its [43 technical briefing](#), the UK Health Security Agency reported model estimates of hospitalization rate per infection (IHR) over time.

Recent data shows an uptick:


BA.4 & BA.5 or waning immunity?




Uncertain news

Factors determining the height of the BA.4/BA.5 wave

4. Public health measures: Lowest since the pandemic began and little appetite



Not great news



Prepare the public: We are at the start of the BA.4/BA.5 wave

Encourage boosters: Don't wait for the bivalent vaccines (Wuhan & Omicron)


- Omicron-specific booster from Moderna shows just a **slight** difference relative to prototype booster, which may have little real-world relevance to vaccine effectiveness (e.g., only 1.75 difference in neutralizing geometric mean titer ratio between boosting with mRNA-1273.214 vs mRNA-1273 [[Moderna June 8 2022 press release](#)]).
- Prioritize bivalent vaccine for immunologically naive individual

Globally prioritize treatment of those suffering persistent infections

- 2-3% of population immunosuppressed
- 40M+ living with HIV/AIDS

The BC COVID-19 Modelling Group works on rapid response modelling of the COVID-19 pandemic, with a special focus on British Columbia and Canada.

The interdisciplinary group, working independently from Government, includes experts in epidemiology, mathematics, and data analysis from UBC, SFU, UVic, and the private sector, with support from the [Pacific Institute for the Mathematical Sciences](#).



<https://bccovid-19group.ca>

Thank you



Coronavirus Variants
Rapid Response
Network



Réseau de réponse
rapide aux variants
du coronavirus

